A therapeutic vaccination method includes growing and harvesting viruses, bacteria, fungi, parasites, or tumor cells on a cell culture or other appropriate medium; killing the viruses, bacteria, fungi, parasites, or tumor cells in the cell culture or other appropriate medium with a dose of methylene blue; separating the dead viruses, bacteria, fungi, parasites, or tumor cells from a remainder of the cell culture or other appropriate medium using a filter and/or centrifuge; adding antivirals, antibacterials, antifungals, antiparasitics, and/or anti-neoplastic medications at non-toxic therapeutic concentrations to the dead viruses, bacteria, fungi, parasites, or tumor cells so as to form a therapeutic vaccine; and administering the therapeutic vaccine to a patient in need thereof to simultaneously produces a therapeutic response and a humoral and cellular immune response in the body of the patient without resulting in deleterious side effects to the patient.

A contact lens product having a cornea repair function includes a composition in the form of a solution. The composition includes gold nanoparticles and at least one auxiliary repairing ingredient. The gold nanoparticles are present in an effective concentration from 0.01 ppm to 3000 ppm and have an average particle size from 0.01 nm to 100 nm. The at least one auxiliary repairing ingredient is selected from the group consisting of chondroitin sulfate, α-lipoic acid, 2-aminoethanesulfonic acid, and potassium L-aspartate and present in an amount greater than 0 wt % and less than 20 wt % based on the composition being 100 wt %.

A contact lens product having a cornea repair function includes a composition in the form of a solution. The composition includes gold nanoparticles and at least one auxiliary repairing ingredient. The gold nanoparticles are present in an effective concentration from 0.01 ppm to 3000 ppm and have an average particle size from 0.01 nm to 100 nm. The at least one auxiliary repairing ingredient is selected from the group consisting of chondroitin sulfate, α-lipoic acid, 2-aminoethanesulfonic acid, and potassium L-aspartate and present in an amount greater than 0 wt % and less than 20 wt % based on the composition being 100 wt %.

A contact lens product having a cornea repair function includes a composition in the form of a solution. The composition includes gold nanoparticles and at least one auxiliary repairing ingredient. The gold nanoparticles are present in an effective concentration from 0.01 ppm to 3000 ppm and have an average particle size from 0.01 nm to 100 nm. The at least one auxiliary repairing ingredient is selected from the group consisting of chondroitin sulfate, α-lipoic acid, 2-aminoethanesulfonic acid, and potassium L-aspartate and present in an amount greater than 0 wt % and less than 20 wt % based on the composition being 100 wt %.

The present invention relates to a gold nanoparticle-containing medicine, and a treatment of a proliferative disease using the medicine. The present invention also relates to a gold nanoparticle-containing medicine that is bound to an alpha radioactive nucleus, and a treatment of a proliferative disease using the medicine.

The present invention relates to a gold nanoparticle-containing medicine, and a treatment of a proliferative disease using the medicine. The present invention also relates to a gold nanoparticle-containing medicine that is bound to an alpha radioactive nucleus, and a treatment of a proliferative disease using the medicine.

The present disclosure relates to a herbo-mineral metallic pharmaceutical kit and a process for its preparation. The herbo-mineral metallic pharmaceutical kit comprises Suvarna Bhasmadi Vati (SBV), Mouktikyukta Kamdudha Vati (MKV), Trailokyachintamani Rasa Vati (TCR), Kumari Kalpa Vati (KKV) and Khadirarishta (KHA). The herbo-mineral metallic pharmaceutical kit of the present disclosure can be used for delaying and/or controlling the recurrence or occurrence of breast and/or ovarian cancer in second breast and/or ovary or metastasis. The herbo-mineral metallic pharmaceutical compositions of the kit assist in reducing oxidative stress, improving immune status and quality of life and maintaining a disease-free survival in patients who are genetically predisposed to breast or ovarian cancer.

The present disclosure relates to a herbo-mineral metallic pharmaceutical kit and a process for its preparation. The herbo-mineral metallic pharmaceutical kit comprises Suvarna Bhasmadi Vati (SBV), Mouktikyukta Kamdudha Vati (MKV), Trailokyachintamani Rasa Vati (TCR), Kumari Kalpa Vati (KKV) and Khadirarishta (KHA). The herbo-mineral metallic pharmaceutical kit of the present disclosure can be used for delaying and/or controlling the recurrence or occurrence of breast and/or ovarian cancer in second breast and/or ovary or metastasis. The herbo-mineral metallic pharmaceutical compositions of the kit assist in reducing oxidative stress, improving immune status and quality of life and maintaining a disease-free survival in patients who are genetically predisposed to breast or ovarian cancer.

Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.

Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.